A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Autosomal Dominant Polycystic Kidney Disease Clinical Trial

Official title:

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00841568
• Other study ID #: 156-05-002
• Secondary ID: JapicCTI-090690
• Status: Completed
• Phase: Phase 2
• Start date: April 2006
• Est. completion date: November 2010

Study information

• Verified date: August 2018
• Source: Otsuka Pharmaceutical Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).

Description:

Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients who completed 5-day repeated administrations and the follow-up observation in the preceding study (156-04-001)

• Patients in whom the safety of repeated administration was confirmed based on the investigator's reports from the preceding study (156-04-001)

Exclusion Criteria:

• Patients with serum creatinine concentration of 2.5 mg/dL or higher at the screening examination

• Patients with any of the following complications

• Uncontrolled hypertension

• Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)"

• Patients with any of the following complications or history thereof

• Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity thereto)

• Inability to personally give consent due to a mental disease "

• Patients with SBP (in sitting position) <90 mm Hg (at screening examination)

• Patients with history of massive bleeding or bleeding tendency

• Patients with a history of drug or alcohol abuse within 6 months prior to the screening examination

• Pregnant women, lactating women, or women who may become or plan to become pregnant

• Patients who received any investigational drug other than OPC-41061 within 30 days prior to commencement of administration of OPC-41061

• Any patient who, in the opinion of the principle investigator or attending investigators, should not participate in the study

Related Conditions & MeSH terms

• Autosomal Dominant Polycystic Kidney Disease
• Kidney Diseases
• Polycystic Kidney Diseases
• Polycystic Kidney, Autosomal Dominant

Intervention

Drug:
• OPC-41061
orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Otsuka Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Kidney Volume	Individual subject data on the volumes of the total kidney volume (sum of the volumes of the left and right kidneys) measured by magnetic resonance imaging or computed tomography during trial period.; Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.	Baseline, week 24, 52, 104, and 156
Primary	Renal Function Test (eGFR)	Individual subject data on eGFR (estimated glomerular filtration rate calculated by Japanese eGFR equation) during trial period.; Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.	Baseline, Week 24, 48, 104, and 156